ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2014

A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer.

Steven H Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.